key: cord-0315058-ksvrceaf
authors: Chiozzini, Chiara; Manfredi, Francesco; Ferrantelli, Flavia; Leone, Patrizia; Giovannelli, Andrea; Olivetta, Eleonora; Federico, Maurizio
title: CD8+ T cell immunogenicity induced by endogenous EVs engineered by antigens fused to a truncated Nefmut EV-anchoring protein
date: 2021-02-06
journal: bioRxiv
DOI: 10.1101/2021.02.05.429891
sha: 1890f43a5741028a1d179abf1a9472d2838b03d7
doc_id: 315058
cord_uid: ksvrceaf

Intramuscular injection of DNA vectors expressing the extracellular vesicle (EV)-anchoring protein Nefmut fused at its C-terminus to viral and tumor antigens elicits a potent, effective, and anti-tolerogenic CD8+ T cell immunity against the heterologous antigen. The immune response is induced through the production of EVs incorporating Nefmut-derivatives released by muscle cells. In the perspective to a possible translation into the clinic of the Nefmut-based vaccine platform, we aimed at increasing its safety profile by identifying the minimal part of Nefmut retaining the EV-anchoring protein property. We found that a C-terminal deletion of 29-amino acids did not affect the ability of Nefmut to associate with EVs. Furthermore, the EV-anchoring function was preserved when antigens from both HPV16 (i.e., E6 and E7) and SARS-CoV-2 (i.e., S1 and S2) were fused to its C-terminus. By analyzing the immune responses induced after intramuscular injection of DNA vectors expressing fusion products based on the four viral antigens, we found that the Nefmut C-terminal deletion did not impact on the levels of antigen –specific CD8+ T lymphocytes as evaluated by IFN-γ EliSpot analysis and intracellular cytokine staining. In addition, immune responses at distal sites remained unaffected, as indicated by the similar percentages of SARS-CoV-2 S1- and S2-specific CD8+ T cells detected in spleens and lung airways of mice injected with DNA vectors expressing the viral antigens fused with either Nefmut or NefmutPL. We concluded that the C-terminal Nefmut truncation does not affect stability, EV-anchoring, and CD8+ T cell immunogenicity of the fused antigen. Hence, NefmutPL represents a safer alternative to full-length Nefmut for the design of CD8+ T cell vaccines for humans.

Extracellular vesicles (EVs) are classified as apoptotic bodies (1-5 m) , microvesicles (50-1,000 nm), and exosomes (50-200 nm) (1) . Microvesicles (also referred to as ectosomes) shed by plasma membrane, whereas exosomes are released after inward invagination of endosome membranes and formation of intraluminal vesicles. Exosomes are secreted by all cell types and are an important mean of intercellular communication by transporting their cargo, such as DNAs, RNAs, proteins, and lipids, from the producer cell to the recipient one (2) . Healthy cells constitutively release both exosomes and microvesicles, together referred to as EVs hereinafter.

Nef mut is a Human Immunodeficiency Virus-1 protein mutant defective for all anti-cellular Nef functions including CD4 and MHC Class I down-regulation, increased HIV-1 infectivity, and p21 activated kinases (PAK)-2 activation (3). We previously described the high efficiency of HIV-1 Nef mut of uploading into EVs released by multiple cell types (4) . The efficiency of Nef mut incorporation into EVs is maintained also when a foreign protein is fused to its C-terminus (5) (6) (7) . When DNA vectors expressing Nef mut -based fusion proteins are intramuscularly (i.m.) injected in mice, significant quantities of the fusion proteins are packed into EVs while not altering their spontaneous release from muscle tissue. These in vivo engineered EVs can freely circulate into the body, and internalized by antigen-presenting cells (APCs) which cross-present EV contents to activate antigen-specific CD8 + T cells. These events result in the induction of potent antigen-specific CD8 + T cytotoxic lymphocyte (CTL) responses (6) (7) (8) . Effectiveness and flexibility of this vaccine platform have been demonstrated with an array of viral products of various origins and sizes including but not limited to: Human Papilloma virus (HPV)16-E6 and -E7; Severe acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 S1, S2, M, and N; Ebola Virus VP24, VP40 and NP; Hepatitis C Virus NS3; West Nile Virus NS3; and Crimean-Congo Hemorrhagic Fever NP (7) .

To maximize the safety profile of the Nef mut -based immunogens, we tried to identify the minimum part of Nef mut still retaining in full the efficiency of EV-anchoring protein and the associated EV immunogenicity. Investigations were carried out in the context of two viral systems recognizing quite different pathogenic effects, i.e., HPV-16, whose infection can induce tumors, and the acute respiratory disease-inducing SARS-CoV-2.

Pre-clinical studies already provided evidence that the Nef mut -based CTL vaccine platform can be exploited as therapeutic intervention against HPV16-related and other malignancies (6, 9) . The benefits expected from a therapeutic cancer vaccine refer to the possibility to induce a de novo antitumor immunity as well as widen both potency and breadth of pre-existing immunity (10) . Cancer cells can express a multitude of new antigens as result of their intrinsic genetic instability typical of malignant transformation and/or of the expression of the etiologic cancer agents, as in the case of virus-induced malignancies, e.g., HPV and HBV.

In non-virus-induced cancers, transformed cells can produce antigens to which the host is basically tolerant (tumor-associated self-antigens) as in the case of antigens expressed during fetal development (oncofetal antigens), and overexpressed in specific tissues, e.g., HER2 in mammary glands. In addition, cancer cells can express antigens to which the host does not develop tolerance, being however the immune response is not effective enough to counteract the cancer cell growth. They include the so-called "tumor specific neoantigens" as well as antigens normally produced in immune-privileged tissues, as for cancer-testis antigens (11) . Hence, establishing a safe method to induce an adaptive immune response against both tolerogenic and non-tolerogenic TAAs would be of great relevance for the design of novel antitumor therapeutic approaches.

Previous work demonstrated the role of specific CD8 + T cell immunity in attenuating the disease induced by influenza virus (12, 13) . Similarly, both experimental and clinical evidences supported the idea that a SARS-CoV-2-specific CD8 + T cell immunity can be instrumental to at least strongly mitigate the symptoms related to the viral spread in both upper and lower airways (14) (15) (16) . Data from experimental infections in rhesus macaques indicated that the virus-specific CD8 + T cell immunity is critical to protect the animals from virus re-challenge after the rapid decay of neutralizing antibodies (17) . Consistently, induction of antiviral CD8 + T cells was associated with a strongly reduced severity of the disease in humans (18) .

Furthermore, the demonstrated ability of SARS-CoV-2 to spread through cell-to-cell contact (19) implies the necessity to induce a robust cellular immunity to contain and clear the virus. In this context, the development of novel preventive strategies focused on the induction of anti-SARS-CoV-2 CD8 + T cell immunity would be considered of relevance.

The Nef mut -based CTL vaccine platform has been already proven to be a candidate for both antiviral and antitumor vaccines. In this perspective, optimization of the safety profile of Nef mut -based immunogens is mandatory. This aim can be pursued, for instance, by removing unnecessary sequences from the anchoring protein. Here, we provide evidence that both EV-incorporation efficiency and immunogenicity of foreign antigens are conserved in the presence of a C-terminal 29 amino acid deletion of Nef mut .

The pTargeT (Invitrogen, Thermo Fisher Scientific) Nef mut and Nef mut fusion vectors were already described (5, 6) . The pTargeT-Nef mut /E6 vector comprised an E6 ORF which was codon optimized through an ad hoc algorithm provided by Codon Optimization On-Line (COOL) service (https://cool.syncti.org) which introduced 134 base substitutions. In addition, the G 130 V amino acid substitution generated a loss-offunction of E6 by hindering its interaction with the p53 cell protein partner (20) . The E6 ORF was inserted in Apa I/Sal I sites of the pTargeT-Nef mut fusion vector. The pTargeT-Nef mut /E7 vector was obtained through a similar strategy. The E7 ORF was codon optimized through the introduction of 64 base substitutions as described by Cid-Arregui and coll. (21) . The protein was detoxified through the insertion of three amino acid substitutions, namely three glycines at positions 21, 24, and 26, within the retinoblastoma protein (pRB) binding site. In this way, the E7-specific immortalizing activity was abrogated (21) .

The pTargeT-Nef mut PL vector was obtained starting from the vector pTargeT-Nef mut . It was digested with Sma I which cuts just downstream to the most C-terminal typical Nef mut mutation (i.e., E 177 G ), and at the 3' end of vector polylinker. The subsequent re-ligation generated a C-terminal 29 amino acid deletion, with a de novo formation of a stop codon just downstream the Sma I restriction site.

To obtain the pTargeT Nef mut -PL-based DNA vectors, an intermediate construct referred to as Nef mut PLfusion was obtained. To this aim, the Nef mut PL ORF from pTargeT-Nef mut PL was PCR amplified using a forward primer tagged with a Nhe I restriction site, and a reverse primer including an Apa I site as well as the overlapping sequence for a GPGP linker. The PCR product was then inserted in the corresponding sites of pTargeT vector. In this way, the insertion in the unique Apa I restriction site of downstream ORFs resulted in an in-frame sequence. To obtain the pTarget-Nef mut PL/E6 and pTarget-Nef mut PL/E7 vectors, synthesis and cloning strategy were identical to that described for the DNA vectors expressing the full-length Nef mut .

Both Nef mut /SARS-CoV-2-based fusion proteins were cloned into the pVAX1 plasmid (Thermo Fisher) as already described (22) . Both pVAX1-Nef mut and pVAX1-Nef mut PL vectors were obtained by inserting the respective ORFs in Nhe I and Eco RI sites of the vector polylinker. To obtain pVAX1 vectors expressing Nef mut PL fused with either SARS-CoV-2 S1 and S2 ORFs, an intermediate construct referred to as pVAX1-Nef mut PLfusion was obtained. To this aim, the Nef mut PL ORF from pTargeT-Nef mut PL was PCR amplified using a forward primer tagged with a Nhe I restriction site, and a reverse primer including an Apa I as well as the overlapping sequence for a GPGP linker, and inserted in the corresponding sites of pVAX1 vector. In this way, the downstream insertion of S1 and S2 ORFs in Apa I and Pme I restriction sites resulted in in-frame sequences, and, upon translation, in Nef mut PL-based fusion proteins. Gene synthesis were carried out by Eurofins Genomics and Explora Biotech.

Human embryonic kidney (HEK)293T cells (ATCC, CRL-11268) were grown in DMEM (Gibco) plus 10% heat-inactivated fetal calf serum (FCS, Gibco). Transfection assays were performed using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific).

Cells transfected with vectors expressing the Nef mut -based fusion proteins were washed 24 h later, and reseeded in medium supplemented with EV-deprived FCS. The supernatants were harvested from 48 to 72 h after transfection. EVs were recovered through differential centrifugations (23) by centrifuging supernatants at 500×g for 10 min, and then at 10,000×g for 30 min. Supernatants were harvested, filtered with 0.22 m pore size filters, and ultracentrifuged at 70,000×g for l h. Pelleted vesicles were resuspended in 1×PBS, and ultracentrifuged again at 70,000×g for 1 h. Afterwards, pellets containing EVs were resuspended in 1:100 of the initial volume.

Western blot analyses of both cell lysates and EVs were carried out after resolving samples in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). In brief, the analysis on cell lysates was performed by washing cells twice with 1×PBS (pH 7.4) and lysing them with 1x SDS-PAGE sample buffer. Samples were resolved by SDS-PAGE and transferred by electroblotting on a 0.45 μM pore size nitrocellulose membrane (Amersham) overnight using a Bio-Rad Trans-Blot. For western blot analysis of EVs, they were lysed and analyzed as described for cell lysates. For immunoassays, membranes were blocked with 5% non-fat dry milk in PBS containing 0.1% Triton X-100 for 1 h at room temperature, then incubated overnight at 4 °C with specific antibodies diluted in PBS containing 0.1% Triton X-100. Filters were revealed using 1:1,000-diluted sheep anti-Nef antiserum ARP 444 (MHRC, London, UK), 1:500diluted anti--actin AC-74 mAb from Sigma, and 1:500 diluted anti-Alix H-270 polyclonal Abs from Santa Cruz.

Both 6-weeks old C57 Bl/6 and, for Nef mut /S2 immunizations (in view of the lack of already characterized H2 b immunodominant S2 epitopes), Balb/c female mice were obtained from Charles River. Immunizations were repeated after 14 days. Fourteen days after the second immunization, mice were sacrificed by either cervical dislocation or CO 2 inhalation.

Spleens were explanted by qualified personnel of the ISS Central Animal Facility, and placed into a 2 mL Eppendorf tubes filled with 1 mL of RPMI 1640 (Gibco), 50 µM 2-mercaptoethanol (Sigma). Spleens were transferred into a 60 mm Petri dish containing 2 mL of RPMI 1640 (Gibco), 50 µM 2-mercaptoethanol (Sigma). Splenocytes were extracted by incising the spleen with sterile scissors and pressing the cells out of the spleen sac with the plunger seal of a 1 mL syringe. After addition of 2 mL of RPMI medium, cells were transferred into a 15 mL conical tube and the Petri plate was washed with 4 mL of medium to collect the remaining cells. After a three-minute sedimentation, splenocytes were transferred to a new sterile tube to remove cell/tissue debris. Counts of live cells were carried out by the trypan blue exclusion method. Fresh splenocytes was resuspended in RPMI complete medium, containing 50 µM 2-mercaptoethanol and 10% FBS, and tested by IFN-γ EliSpot assay.

For bronchoalveolar lavages, mice were sacrificed by CO 2 inhalation, placed on their back, and dampened with 70% ethanol. Neck skin was opened to the muscles by scissors, and muscles around the neck and salivary glands were gently pulled aside with forceps to expose the trachea. A 15 cm long surgical thread was then placed around the trachea and a small hole was cut by fine point scissors between two cartilage rings. A 22 G × 1" Exel Safelet Catheter was carefully inserted about 0.5 cm into the hole, and then the catheter and the trachea were firmly tied together with the suture. A 1 mL syringe was loaded with 1 mL of cold PBS and connected to the catheter. The buffered solution was gently injected into the lung and aspirated while massaging mouse torax. Lavage fluid was tranferred to a 15 mL conical tube on ice, and lavage repeated two more times (24, 25) . Total lavage volume was approximately 2.5 mL/mouse. Cells were recovered by centrifugation, resuspeded in cell culture medium, and counted.

A total of 2. N. B5655. The spot-forming cells were finally analyzed and counted using an AELVIS EliSpot reader.

Splenocytes were seeded at 2×10 6 /mL in RPMI medium, 10% FCS, 50 µM 2-mercaptoethanol 

When appropriate, data are presented as mean + standard deviation (SD). In some instances, the Mann-Whitney U test was used. p<0.05 was considered significant.

The reduction of sequences of the EV-anchoring protein is expected to increase the safety profile of the Nef mut CTL vaccine platform. We tried to identify the shortest Nef mut -related amino acid sequence still retaining the ability to efficiently incorporate into EVs.

HIV-1 Nef is a 206 to 210 amino acid long protein recognizing a quite extended structured Nmoiety, and an unstructured C-terminal flexible region (31) . To leave untouched the Nef mut secondary structure which was assumed to be necessary for the EV-uploading activity, only isoforms deleted within its unstructured C-terminus were considered. Another relevant constraint was represented by the most Cterminal unique amino acid mutation of Nef mut which maps at position 177, and whose presence was proven to be mandatory to preserve its high efficiency of EV uploading. On this basis, a Nef mut protein truncated at the amino acid 178, hence deprived of 29 C-terminal amino acids, was considered (Fig. 1) .

Both cell accumulation and EV association of C-terminal truncated Nef mut (hereinafter referred to as Nef mut PL) compared to the full-length isoform were analyzed. To this aim, western blot analysis on lysates of both transiently transfected HEK293T cells and EVs isolated from respective supernatants were carried out.

Representative results shown in fig. 2 indicated that Nef mut and Nef mut PL accumulated into transfected cells at similar extents, suggesting that the C-terminal truncation did not affect the protein stability. Most important, Nef mut PL associated with EVs at levels comparable to those of full-length Nef mut , indicating that the presence of the 29 C-terminal amino acids is not essential for the uploading efficiency of Nef mut into EVs.

Next, we tested the efficiency of EV-uploading of foreign proteins fused to Nef mut PL compared to parental Nef mut . To this aim, we considered both HPV16-E6 and -E7, which were already shown to be uploaded in EVs upon fusion with full-length Nef mut (7, 32) . The Nef mut -related sequences were fused with either HPV16-E6 or -E7 ORFs which were optimized for translation in eukaryotic cells, and whose protein domains involved in the respective pathogenic effects were inactivated. Steady-state levels in both transfected cells and EVs isolated from the respective supernatants were evaluated by western blot analysis.

The E6-based fusion products accumulated in HEK293T transfected cells at similar levels, and the analysis of EVs revealed that E6 efficiently associated with EVs also when fused with Nef mut PL (Fig. 3A) .

Consistently, E7 derivatives fused with either Nef mut or Nef mut PL were expressed and uploaded in EVs at similar extents (Fig. 3B) .

We concluded that the presence of the C-terminal 29 amino acids of Nef mu is not essential for the efficient EV-uploading of the HPV16 products fused to it.

The induction of strong CTL immunity through the Nef mut -based platform against the heterologous antigen implies the induction of antigen-specific CD8 + T lymphocytes co-expressing inflammatory Th-1 cytokines including IFN-γ, IL-2, and TNF-α (i.e., polyfunctional CD8 + T lymphocytes). Next, we compared the effectiveness of Nef mut to that of its truncated form in favoring the antigen-specific CD8 + T cell immune response against the foreign antigen also in terms of induction of polyfunctional CD8 + T lymphocytes.

DNA vectors expressing HPV16-E6 and-E7 fused with either Nef mut or Nef mut PL were injected in mice. Fourteen days after the second immunization, IFN-γ EliSpot assays showed that all injected mice responded in terms of antigen-specific CD8 + T cell immunity (Fig. 4A) . Overall, DNA vectors expressing E7-derivatives induced stronger immune responses compared to E6-derivatives. On the other hand, the levels of CD8 + T cell immune response in mice immunized with Nef mut PL-based vectors appeared similar to those detected after injection of DNA vectors expressing full-length Nef mut (Fig. 4A) . Single-cytokine ICS analysis showed that the percentages of E6/E7-specific CD8 + T lymphocytes expressing either IFN-γ, IL-2, or TNF-α did not significantly change in the presence of Nef mut or Nef mut PL. As an exception, increased percentages of TNF-α expressing CD8 + T cells were observed from mice injected with DNA expressing Nef mut PL/E6 compared to those immunized with Nef mut /E6 (Fig. 4B ). Most important, the C-terminal truncation of Nef mut did not affect the generation of antigen-specific, polyfunctional CD8 + T lymphocytes ( fig. 4C ).

We concluded that the effectiveness of the Nef mut -based vaccine platform in terms of anti-HPV16-E6 and -E7 immunogenicity remained largely unchanged when the anchoring protein was deleted of its 29 Cterminal amino acids.

Very recently we demonstrated that the Nef mut -based vaccine platform could be instrumental to induce strong CD8 + T cell immunity against multiple SARS-CoV-2 antigens (22) . The immune response was detected in both spleens and lung airways. To establish whether these immunogenic properties were preserved also in the presence of the Nef mut C-terminal truncation, we first evaluated the EV-uploading efficiency of the fusion products. Investigations were carried out with both S1 and S2 SARS-CoV-2 antigens, which were proven to be the most immunogenic antigens in the context of the Nef mut vaccine platform.

cells, and the relative levels of uploading into EVs were scored upon their isolation from the supernatants.

Results from western blot assays indicated that S1 and S2 accumulated in cells at comparable extents when fused with the two EV-anchoring proteins (Fig. 5) . Most important, no evident differences in the levels of EV-uploading were assessed (Fig. 5) .

As already observed with HPV16 products, also in the case of SARS-CoV-2 antigens the efficiency of EV uploading was not influenced by the Nef mut C-terminal truncation.

Both SARS-CoV-2 S1 and S2 were previously shown to induce a strong CD8 + T cell immunity in both spleens and lung airways when expressed by a DNA vector as product of fusion with Nef mut (22) . Next, we compared the CD8 + T cell responses following the injection of DNA vectors expressing the two antigens fused with either Nef mut or Nef mut -PL. Fourteen days after the second immunization, splenocytes were isolated from injected mice, and cultured overnight in IFN-γ EliSpot microwells. Comparable antigenspecific CD8 + T cell activations were observed in splenocytes from mice inoculated with each vector expressing the diverse fusion products, in the presence of a slight increase with vectors expressing fulllength Nef mut (Fig. 7A) . On the other hand, the levels of immune responses measured in cells isolated from bronchoalveolar lavage fluids (BALFs) of injected mice appeared similar, in this case with a small increase in cells from mice injected with Nef mut PL-based vectors (Fig. 7B) .

These data strongly supported the idea that the Nef mut C-terminus is dispensable for the induction of SARS-CoV-2 specific immunity in spleens and, more striking, lung airways, i.e., the peripheral tissue primarily involved in SARS-CoV-2-related pathogenesis. Hence, Nef mut PL could be considered as an effective and safe alternative to full-length Nef mut for anti-SARS-CoV-2 CTL vaccines based on the technology of endogenously engineered EVs.

The possibility to translate into the clinic the Nef mut -based CTL vaccine platform imposes the need to identify and eliminate unnecessary sequences in both vectors and ORFs coding for the fusion products.

Concerning the DNA vector, we proved that Nef mut -based fusion antigens maintain unaltered their immunogenic properties when expressed by the pVAX1 vector (22) , i.e., a vector where prokaryotic sequences are reduced compared to the more complex pTargeT vector we previously utilized. More advanced, extremely small DNA vectors lacking antibiotic resistance (e.g., minicircle DNA vectors) would represent an interesting alternative for translation into the clinic of the Nef mut -based vaccine platform (33) .

On the other hand, the possibility to reduce the sequences required for the efficient EV-uploading was here explored. Although we largely documented that Nef mut lacks all biologic activities of the wild-type counterpart (3), it should be considered that its defectiveness relies on the co-existence of two amino acid substitutions. Unpredictable, rare, however theoretically possible events of back-mutation might occur, especially when the immunogenic DNA undergoes large-scale production and delivery. In this context, possible anti-cellular effects due to back-mutations are expected to be strongly mitigated by the deletion of a significant part of the protein. In particular, the 29 amino acid C-terminal region of Nef includes domains involved in both signaling and trafficking functions typical of wt Nef (34) . In the case of Nef mut , we found that the truncation of a C-terminal region of 29 amino acids had no impact on both efficiency of EV uploading and immunogenicity of diverse fusion products. This conclusion can be applied to any foreign antigen, since it was drawn through the analysis of both small-and large-sized proteins from unrelated viruses.

In some instance, our results can be considered unexpected since the Nef C-terminal region comprises a well conserved cholesterol recognizing motif (CRM) already characterized as an important domain for the association with the viral envelope (35) . Considering the convergence in the biogenesis of HIV-1 and EVs (36) , this domain has the potential to play a role in the interaction of Nef with the nanovesicles released by Nef-expressing cells. The CRM amino acid sequence, i.e., LHPEYYK in SF2-like Nef alleles and LHPEYFK in HXB2-like ones, is well conserved among HIV-1 types B strains, including that from which Nef mut originated, i.e., F12/HIV-1 (37) . We hypothesized that the effects of both N-terminal myristoylation and palmitoylation present in Nef mut , together with the stretch of basic amino acids located in alpha helix 1 are prevalent over those induced by CRM in terms of stable interaction with lipid rafts of both plasma and endosomal membranes.

Overall, the possibility to include Nef mut PL sequences in DNA vectors candidates for new vaccine strategies against infectious and tumor diseases significantly strengthens the safety profile of the EV-based CTL vaccine platform.

We thank Antonio Di Virgilio and Pietro Arciero, Istituto Superiore di Sanità, for technical support.

This work was supported by the grant PGR00810 from Ministero degli Affari Esteri e della Cooperazione Internazionale, Italy.

The authors declare no conflict of interest. For both panels, polyclonal anti-Nef Abs served to detect Nef mut -based products, while -actin and Alix were markers for cell lysates and EVs, respectively. Molecular markers are given in kDa. EVs. Western blot analysis on 30 g of lysates from HEK293T cells transfected with DNA vectors expressing either Nef mut or Nef mut PL fused with either SARS-CoV-2 S1 or S2 ORFs (upper panels).

Equal volumes of buffer where purified EVs were resuspended after differential centrifugations of the respective supernatants were also analyzed (bottom panels). As control, conditions from mocktransfected cells as well as cells transfected with a vector expressing Nef mut and/or Nef mut PL were included. Polyclonal anti-Nef Abs served to detect Nef mut -based products, while -actin and Alix were revealed as markers for cell lysates and EVs, respectively. Relevant signals are highlighted. Molecular markers are given in kDa. The results are representative of two independent experiments. 

Shedding Light on the

The Multifaceted Functions of Exosomes in Health and Disease: An Overview

Genetic and Functional Analysis of the Human Immunodeficiency Virus (HIV) Type 1-Inhibiting F12-HIVnef Allele

A Strategy of Antigen Incorporation into Exosomes: Comparing Cross-Presentation Levels of Antigens Delivered by Engineered Exosomes and by Lentiviral Virus-like Particles

DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors

Antitumor HPV E7-Specific CTL Activity Elicited by in Vivo Engineered Exosomes Produced through DNA Inoculation

An Exosome-Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens

HPV-E7 Delivered by Engineered Exosomes Elicits a Protective CD8 + T Cell-Mediated Immune Response

Engineered Exosomes Emerging from Muscle Cells Break Immune Tolerance to HER2 in Transgenic Mice and Induce Antigen-Specific CTLs upon Challenge by Human Dendritic Cells

The Blockade of Immune Checkpoints in Cancer Immunotherapy

The Future of Cancer Treatment: Immunomodulation, CARs and Combination Immunotherapy

Cellular Immune Correlates of Protection against Symptomatic Pandemic Influenza

Cytotoxic T-Cell Immunity to Influenza

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 That Largely Reside Outside the Spike Protein

Convalescent Individuals

Correlates of Protection against SARS-CoV-2 in Rhesus Macaques

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury

HAda3 Degradation by Papillomavirus Type 16 E6 Correlates with Abrogation of the P14ARF-P53 Pathway and Efficient Immortalization of Human Mammary Epithelial Cells

A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies

A New Concept on Anti-SARS-CoV-2 Vaccines: Strong CD8 + T-Cell Immune Response in Both Spleen and Lung Induced in Mice by Endogenously Engineered Extracellular Vesicles

Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids

Immunity to Respiratory Viruses

Interstitial-Resident Memory CD8+ T Cells Sustain Frontline Epithelial Memory in the Lung

Identification of H-2Kb Binding and Immunogenic Peptides from Human Papilloma Virus Tumour Antigens E6 and E7

Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine

Public" T-Helper Epitope of the E7 Transforming Protein of Human Papillomavirus 16 Provides Cognate Help for Several E7 B-Cell Epitopes from Cervical Cancer-Associated Human Papillomavirus Genotypes

Identification of Murine CD8 T Cell Epitopes in Codon-Optimized SARS-Associated Coronavirus Spike Protein

Priming with SARS CoV S DNA and Boosting with SARS CoV S Epitopes Specific for CD4+ and CD8+ T Cells Promote Cellular Immune Responses

How HIV Nef Proteins Hijack Membrane Traffic To Promote Infection

The CD8 + T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant. Vaccines (Basel)

Two Sorting Motifs, a Ubiquitination Motif and a Tyrosine Motif, Are Involved in HIV-1 and Simian Immunodeficiency Virus Nef-Mediated Receptor Endocytosis

Nef Increases the Synthesis of and Transports Cholesterol to Lipid Rafts and HIV-1 Progeny Virions

Exosomes and Other Extracellular Vesicles in Host-Pathogen Interactions

Biologic and Molecular Characterization of Producer and Nonproducer Clones from HUT-78 Cells Infected with a Patient HIV Isolate